Mihalekné Fűr, Gabriella and Nemes, Kolos and Magó, Éva and Benő, Alexandra Ágnes and Topolcsányi, Petronella and Moldvay, Judit and Pongor, Lőrinc (2024) Applied models and molecular characteristics of small cell lung cancer. PATHOLOGY AND ONCOLOGY RESEARCH, 30. pp. 1-13. ISSN 1219-4956
|
Text
pore-30-1611743.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
Small cell lung cancer (SCLC) is a highly aggressive type of cancer frequently diagnosed with metastatic spread, rendering it surgically unresectable for the majority of patients. Although initial responses to platinum-based therapies are often observed, SCLC invariably relapses within months, frequently developing drug-resistance ultimately contributing to short overall survival rates. Recently, SCLC research aimed to elucidate the dynamic changes in the genetic and epigenetic landscape. These have revealed distinct subtypes of SCLC, each characterized by unique molecular signatures. The recent understanding of the molecular heterogeneity of SCLC has opened up potential avenues for precision medicine, enabling the development of targeted therapeutic strategies. In this review, we delve into the applied models and computational approaches that have been instrumental in the identification of promising drug candidates. We also explore the emerging molecular diagnostic tools that hold the potential to transform clinical practice and patient care.
| Item Type: | Article |
|---|---|
| Additional Information: | Cancer Genomics and Epigenetics Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM), Szeged, Hungary Genome Integrity and DNA Repair Core Group, Hungarian Centre of Excellence for Molecular Medicine (HCEMM), Szeged, Hungary Department of Pulmonology, Szeged University Szent-Gyorgyi Albert Medical School, Szeged, Hungary 1st Department of Pulmonology, National Koranyi Institute of Pulmonology, Budapest, Hungary Export Date: 10 June 2024 CODEN: POREF Correspondence Address: Pongor, L.S.; Cancer Genomics and Epigenetics Core Group, Hungary; email: lorinc.pongor@hcemm.eu Chemicals/CAS: gamma interferon inducible protein 10, 97741-20-3; indoleamine 2,3 dioxygenase; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase, 210488-47-4; phosphatidylinositol 4,5 bisphosphate 3 kinase, 103843-30-7; platinum, 7440-06-4; uvomorulin, 112956-45-3; Biomarkers, Tumor Funding details: Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, NKFIA, TKP2021-EGA Funding details: Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, NKFIA Funding details: 739593, 2022-2.1.1-NL-2022-00005, TKP-2021-EGA-05 Funding details: Magyar Tudományos Akadémia, MTA, BO/00697/23 Funding details: Magyar Tudományos Akadémia, MTA Funding text 1: The authors declare that financial support was received for the research, authorship, and/or publication of this article. This research was funded by the J\\u00E1nos Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00697/23 (LP). The project received funding from the EU\\u2019s Horizon 2020 Research and Innovation Program with grant agreement No. 739593. Project nos TKP-2021-EGA-05 and 2022-2.1.1-NL-2022-00005 has been implemented with the support provided by the Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund, funded by the TKP2021-EGA and National Laboratories grant program. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
| Subjects: | R Medicine / orvostudomány > R1 Medicine (General) / orvostudomány általában |
| SWORD Depositor: | MTMT SWORD |
| Depositing User: | MTMT SWORD |
| Date Deposited: | 23 Sep 2024 07:35 |
| Last Modified: | 23 Sep 2024 10:48 |
| URI: | https://real.mtak.hu/id/eprint/205514 |
Actions (login required)
 |
Edit Item |
